Cargando…

Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy

BACKGROUND: To evaluate if conjunctival epithelial cells’ expression of HLA-DR and ICAM-1 could be helpful as early topical markers of inflammation in Graves’ orbitopathy (GO). METHODS: The ocular examination evaluated a clinical activity score (CAS) by assessment of clinical features, (e.g., eyelid...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlowski, P., Mysliwiec, J., Mrugacz, M., Zak, J., Bakunowicz-Lazarczyk, A., Rejdak, R., Wysocka, J., Gorska, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968517/
https://www.ncbi.nlm.nih.gov/pubmed/24562464
http://dx.doi.org/10.1007/s00417-014-2580-z
_version_ 1782309163307630592
author Pawlowski, P.
Mysliwiec, J.
Mrugacz, M.
Zak, J.
Bakunowicz-Lazarczyk, A.
Rejdak, R.
Wysocka, J.
Gorska, M.
author_facet Pawlowski, P.
Mysliwiec, J.
Mrugacz, M.
Zak, J.
Bakunowicz-Lazarczyk, A.
Rejdak, R.
Wysocka, J.
Gorska, M.
author_sort Pawlowski, P.
collection PubMed
description BACKGROUND: To evaluate if conjunctival epithelial cells’ expression of HLA-DR and ICAM-1 could be helpful as early topical markers of inflammation in Graves’ orbitopathy (GO). METHODS: The ocular examination evaluated a clinical activity score (CAS) by assessment of clinical features, (e.g., eyelid or conjunctival inflammation, lid width, lid closure, proptosis, ocular motility). Conjunctival epithelial cell specimens for flow-cytometric evaluations of ICAM-I and HLADR expression were collected by impression cytology from ten eyes with active GO (CAS ≥ 4 and duration ≤ 12 months), from 15 eyes with Graves’ disease (GD) without active GO (CAS 0–2) and from 15 normal specimens without any ocular disorders. RESULTS: The percentage of HLA-DR + conjunctival epithelial cells was significantly elevated in patients with active GO comparing to GD without active GO and healthy controls, 10.7 % (8.5–17.7) and 7.78 % (3.92–10.1) (p < 0.05) vs. control 4.89 % (3.5–5.5) (p < 0.005), respectively. The expression of ICAM − 1+ conjunctival epithelial cells was greater only in patients with GO vs. controls, 5.5 % (4.8–7.03) and 1.46 % (0.69–2.51) (p < 0.005), respectively. CONCLUSION: The percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in patients with the active GO may serve as a topical inflammation marker in Graves’ orbitopathy.
format Online
Article
Text
id pubmed-3968517
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-39685172014-03-28 Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy Pawlowski, P. Mysliwiec, J. Mrugacz, M. Zak, J. Bakunowicz-Lazarczyk, A. Rejdak, R. Wysocka, J. Gorska, M. Graefes Arch Clin Exp Ophthalmol Inflammatory Disorders BACKGROUND: To evaluate if conjunctival epithelial cells’ expression of HLA-DR and ICAM-1 could be helpful as early topical markers of inflammation in Graves’ orbitopathy (GO). METHODS: The ocular examination evaluated a clinical activity score (CAS) by assessment of clinical features, (e.g., eyelid or conjunctival inflammation, lid width, lid closure, proptosis, ocular motility). Conjunctival epithelial cell specimens for flow-cytometric evaluations of ICAM-I and HLADR expression were collected by impression cytology from ten eyes with active GO (CAS ≥ 4 and duration ≤ 12 months), from 15 eyes with Graves’ disease (GD) without active GO (CAS 0–2) and from 15 normal specimens without any ocular disorders. RESULTS: The percentage of HLA-DR + conjunctival epithelial cells was significantly elevated in patients with active GO comparing to GD without active GO and healthy controls, 10.7 % (8.5–17.7) and 7.78 % (3.92–10.1) (p < 0.05) vs. control 4.89 % (3.5–5.5) (p < 0.005), respectively. The expression of ICAM − 1+ conjunctival epithelial cells was greater only in patients with GO vs. controls, 5.5 % (4.8–7.03) and 1.46 % (0.69–2.51) (p < 0.005), respectively. CONCLUSION: The percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in patients with the active GO may serve as a topical inflammation marker in Graves’ orbitopathy. Springer Berlin Heidelberg 2014-02-23 2014 /pmc/articles/PMC3968517/ /pubmed/24562464 http://dx.doi.org/10.1007/s00417-014-2580-z Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Inflammatory Disorders
Pawlowski, P.
Mysliwiec, J.
Mrugacz, M.
Zak, J.
Bakunowicz-Lazarczyk, A.
Rejdak, R.
Wysocka, J.
Gorska, M.
Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title_full Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title_fullStr Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title_full_unstemmed Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title_short Elevated percentage of HLA-DR(+) and ICAM-1(+) conjunctival epithelial cells in active Graves’ orbitopathy
title_sort elevated percentage of hla-dr(+) and icam-1(+) conjunctival epithelial cells in active graves’ orbitopathy
topic Inflammatory Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968517/
https://www.ncbi.nlm.nih.gov/pubmed/24562464
http://dx.doi.org/10.1007/s00417-014-2580-z
work_keys_str_mv AT pawlowskip elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT mysliwiecj elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT mrugaczm elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT zakj elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT bakunowiczlazarczyka elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT rejdakr elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT wysockaj elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy
AT gorskam elevatedpercentageofhladrandicam1conjunctivalepithelialcellsinactivegravesorbitopathy